Table 1: Patient characteristics.

Characteristic Patients (n = 64)
Age (years), median (range) 59.5 (30-82)
Gender, n (%)
Male 0 (0.0)
Female 64 (100.0)
Clinical stage, n (%)
I 7 (10.9)
II 27 (42.2)
III 24 (37.5)
IV 6 (9.4)
Therapeutic response, n (%)
CR 27 (42.2)
PR 8 (12.5)
SD 17 (26.6)
PD 12 (18.7)
DM, n (%)
Present 30 (46.9)
Absent 34 (53.1)
Tissue HER2 status, n (%)
Positive 64 (100.0)
Negative 0 (0.0)
Serum HER2 status, n (%)
Positive 19 (29.7)
Negative 45 (70.3)
Trastuzumab administration, n (%)
Yes 64 (100.0)
No 0 (0.0)

CR: Complete Response; DM: Distant Metastasis; HER2: Human Epidermal Growth Factor Receptor type 2; PD: Progressive Disease; PR: Partial Response; SD: Stable Disease.